Repurposing Ponatinib as a PD-L1 Inhibitor Revealed by Drug Repurposing Screening and Validation by In Vitro and In Vivo Experiments
Author:
Affiliation:
1. Centre for Biomedical Engineering, Indian Institute of Technology, Delhi110016, India
2. Department of Biomedical Engineering, All India Institute of Medical Science, Delhi110029, India
3. National Institute of Immunology, Delhi110067, India
Funder
Indian Institute of Technology Delhi
Publisher
American Chemical Society (ACS)
Subject
Pharmacology (medical),Pharmacology
Link
https://pubs.acs.org/doi/pdf/10.1021/acsptsci.2c00214
Reference37 articles.
1. Comparing antibody and small-molecule therapies for cancer
2. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
3. Immune-related adverse events with immune checkpoint blockade: a comprehensive review
4. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
5. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CD40 agonist engineered immunosomes modulated tumor microenvironment and showed pro-immunogenic response, reduced toxicity, and tumor free survival in mice bearing glioblastoma;Biomaterials;2024-12
2. Simultaneous regulation of AGE/RAGE signaling and MMP-9 expression by an immunomodulating hydrogel accelerates healing in diabetic wounds;Biomaterials Advances;2024-10
3. Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event;Cancers;2024-07-24
4. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma;Expert Opinion on Pharmacotherapy;2024-03-23
5. A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules;Pharmaceuticals;2024-02-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3